Covista (CVSA) Q3 2026 Earnings Transcript

Covista delivered strong Q3 results with revenue up 4.5% to $487 million and adjusted EBITDA of $127.9 million, while total enrollment surpassed 100,000 students for the first time. Management raised full-year revenue guidance to $1.93 billion-$1.945 billion and adjusted EPS guidance to $7.95-$8.15, citing momentum at Chamberlain and Walden, plus solid free cash flow of $336 million over the trailing 12 months. The company also repurchased $66 million of stock, refinanced debt at 50 bps lower rates, and expanded its AI curriculum and employer partnerships.

Analysis

The key signal is not the headline beat; it is that the operating reset at the core franchise appears to be working faster than management modeled, which matters because this is the cleanest way to convert a cyclical enrollment recovery into a longer-duration compounding story. The second-order effect is margin durability: once funnel conversion normalizes, incremental volume should carry unusually high contribution margins, especially as campus expansion and AI-related spending are layered on top of a healthier base. That creates a setup where reported growth can stay resilient even as management continues to spend, reducing the risk that investment intensity masks underlying earnings power.

The more interesting competitive dynamic is employer integration. If the company can turn recruiting relationships into financed pipelines, it shifts demand generation from consumer marketing to quasi-distribution, which is harder for smaller education peers to replicate. The AI curriculum push is less about near-term revenue and more about wedge value: it gives the firm a branded reason to deepen relationships with health systems and could improve student conversion by signaling employability, while also making the platform more defensible if AI fluency becomes a screening criterion in healthcare hiring.

The main risk is that the current guidance raise bakes in continued operational momentum just as capital spending and strategic investments step up. If fall enrollment merely holds rather than accelerates, the market may start to question whether the apparent earnings leverage is being pulled forward from expense timing and calendar effects. In other words, the next catalyst is not another quarter of good numbers; it is proof that the improved conversion rate and employer partnerships are durable enough to support FY27 without needing another re-underwrite.

Consensus may still be underestimating how much of the turnaround is self-help rather than macro. That usually means the stock rerates only after multiple quarters of consistency, not on the first evidence of recovery. The contrarian angle is that the balance sheet and buyback capacity create downside support, so the more asymmetric trade is not chasing an outright breakout, but owning the name while the market is still pricing it as a late-cycle education asset rather than a scaled healthcare workforce platform.

Key Decisions for Investors

• Go long CVSA for 3-6 months ahead of the fall enrollment cycle; the setup is attractive if conversion stays near current levels, with upside from a higher FY27 base and buybacks supporting the stock on pullbacks.
• Buy CVSA Jan-2027 call spreads to express a rerating view while limiting downside if the next quarter is merely stable rather than accelerating; best risk/reward if implied vol remains moderate.
• Pair trade: long CVSA / short a weaker education or workforce-training peer to isolate execution alpha from sector beta; thesis is that this name is showing self-help and capital allocation discipline that peers likely cannot match.
• If the stock gaps up on the guide raise, wait for a 5-8% retracement before adding; the cleaner entry is after the market digests the CapEx step-up and tests whether enrollment momentum is truly repeatable.
• Trim or hedge if fourth-quarter enrollment growth decelerates materially versus Q3; that would suggest the recovery is less durable and that the market may be overpaying for a one-quarter inflection.